v3.25.2
Segment Information (Details)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Mar. 31, 2025
USD ($)
Jun. 30, 2024
USD ($)
Mar. 31, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Operating expenses:            
Number of reportable segments | segment         1  
Total Firmonertinib $ 27,720   $ 21,778   $ 89,009 $ 38,753
Net loss $ (31,399) $ (64,387) $ (21,874) $ (17,417) (95,786) (39,291)
Life science            
Operating expenses:            
Research and development: Discovery-stage programs         44,606 6,614
Research and development: Personnel-related and other internal costs         13,617 7,906
General and administrative: Personnel-related costs         6,792 4,004
General and administrative: Other costs         4,594 3,614
Other segment items         (4,609) (7,080)
Net loss         $ (95,786) (39,291)
Description of other segment item         Other segment items consists of interest and investment income.  
Life science | Firmonertinib            
Operating expenses:            
Other Firmonertinib costs         $ 6,035 1,569
Total Firmonertinib         30,786 24,233
Life science | Further            
Operating expenses:            
Research and development: Firmonertinib (excluding personnel-related and other internal costs):         5,443 7,334
Life science | Furvent            
Operating expenses:            
Research and development: Firmonertinib (excluding personnel-related and other internal costs):         19,235 15,300
Life science | Favour            
Operating expenses:            
Research and development: Firmonertinib (excluding personnel-related and other internal costs):         $ 73 $ 30